BREAKING
Americas Gold and Silver Corporation (USAS) FY2025 Earnings: Misses on EPS, Revenue Recap 3 hours ago FormFactor, Inc. (FORM) Drops 6.1% to $92.00 3 hours ago Photronics, Inc. (PLAB) Drops 6.3% to $37.09 3 hours ago Amkor Technology, Inc. (AMKR) Drops 6.5% to $41.57 3 hours ago Teradyne, Inc. (TER) Drops 5.9% to $277.93 3 hours ago Lumentum Holdings Inc. (LITE) Drops 6.1% to $659.99 3 hours ago MP Materials Corp. (MP) Drops 8% to $47.53 3 hours ago Badger Meter, Inc. (BMI) Jumps 5.1% to $153.31 4 hours ago Palo Alto Networks, Inc. (PANW) Jumps 7.4% to $158 4 hours ago United Therapeutics Corporation (UTHR) Surges 14.8% to $600.09 5 hours ago Americas Gold and Silver Corporation (USAS) FY2025 Earnings: Misses on EPS, Revenue Recap 3 hours ago FormFactor, Inc. (FORM) Drops 6.1% to $92.00 3 hours ago Photronics, Inc. (PLAB) Drops 6.3% to $37.09 3 hours ago Amkor Technology, Inc. (AMKR) Drops 6.5% to $41.57 3 hours ago Teradyne, Inc. (TER) Drops 5.9% to $277.93 3 hours ago Lumentum Holdings Inc. (LITE) Drops 6.1% to $659.99 3 hours ago MP Materials Corp. (MP) Drops 8% to $47.53 3 hours ago Badger Meter, Inc. (BMI) Jumps 5.1% to $153.31 4 hours ago Palo Alto Networks, Inc. (PANW) Jumps 7.4% to $158 4 hours ago United Therapeutics Corporation (UTHR) Surges 14.8% to $600.09 5 hours ago
ADVERTISEMENT
Breaking News

Scienture Holdings Inc (MEDS) Reports FY2025 Earnings

Scienture Holdings Inc (MEDS) posted Q4 2025 basic and diluted EPS of -$2.70.

March 30, 2026 1 min read

Scienture Holdings Inc (MEDS) posted Q4 2025 basic and diluted EPS of -$2.70.

MEDS|EPS -$2.70|Rev $431,609|Net Loss $41.5M

Scienture Holdings Inc (MEDS) posted FY 2025 basic and diluted EPS of -$2.70. Revenue totaled $431,609 for the year. Revenue of $431,609 was up 216.0% year-over-year.

Bottom line showed a net loss of $41.5M.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT